HongKee Sah

Prof. HongKee Sah

Ewha Womans University
orcid

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2013 in Nanomedicine: Nanotechnology, Biology and Medicine
Verified
Journal Article
Closed access
BMBivash Mandal
Bivash Mandal
HBHimanshu Bhattacharjee
Himanshu Bhattacharjee
NMNivesh K Mittal
Nivesh K Mittal
HSHongKee Sah
HongKee Sah
PBPavan Balabathula
Pavan Balabathula
GWGeorge C. Wood
George C. Wood

1 February 2013 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
HSHongKee Sah
HongKee Sah
HDHari R Desu
Hari R Desu
GWGeorge C Wood
George C Wood
THThoma
Thoma
LTLaura A Thoma
Laura A Thoma
ESEdel Sah
Edel Sah
The functionality of bare polylactide-co-glycolide (PLGA) nanoparticles is limited to drug depot or drug solubilization in their hard cores. They have inherent weaknesses as a drug-delivery system. For instance, when administered intravenously, the nanoparticles undergo rapid clearance from systemic circulation before reaching the site of action. Furthermore, plain PLGA nanoparticles cannot distinguish between different cell types. Recent research shows that surface functionalization of nanoparticles and development of new nanoparticulate dosage forms help overcome these delivery challenges and improve in-vivo performance. Immense research efforts have propelled the development of diverse functional PLGA-based nanoparticulate delivery systems. Representative examples include PEGylated micelles/nanoparticles (PEG, polyethylene glycol), polyplexes, polymersomes, core-shell–type lipid-PLGA hybrids, cell-PLGA hybrids, receptor-specific ligand-PLGA conjugates, and theranostics. Each PLGA-based nanoparticulate dosage form has specific features that distinguish it from other nanoparticulate systems. This review focuses on fundamental concepts and practices that are used in the development of various functional nanoparticulate dosage forms. We describe how the attributes of these functional nanoparticulate forms might contribute to achievement of desired therapeutic effects that are not attainable using conventional therapies. Functional PLGA-based nanoparticulate systems are expected to deliver chemotherapeutic, diagnostic, and imaging agents in a highly selective and effective manner.



28 January 2015 in Journal of Nanomaterials
Verified
Journal Article
Open access
PDF file
ESEdel Sah
Edel Sah
HSHongKee Sah
HongKee Sah
In recent years, there have been a plethora of nanoengineering approaches for the development of poly(lactide‐co‐glycolide) (PLGA) nanoparticulate carrier systems. However, overlooking the multifaceted issues in the preparation and characterization of PLGA‐based nanoparticles, many reports have been focused on their in vivo behaviors. It is imperative to fully assess technological aspects of a nanoencapsulation method of choice and to carefully evaluate the nanoparticle quality. The selection of a nanoencapsulation technique should consider drug property, nanoparticle quality, scale‐up feasibility, manufacturing costs, personnel safety, environmental impact, waste disposal, and the like. Made in this review are the fundamentals of classical emulsion‐templated nanoencapsulation methods used to prepare PLGA nanoparticles. More specifically, this review provides insight into emulsion solvent evaporation/extraction, salting‐out, nanoprecipitation, membrane emulsification, microfluidic technology, and flow focusing. Innovative nanoencapsulation techniques are being developed to address many challenges existing in the production of PLGA‐based nanoparticles. In addition, there are various out‐of‐the‐box approaches for the development of novel PLGA hybrid systems that could deliver multiple drugs. Latest trends in these areas are also dealt with in this review. Relevant information might be helpful to those who prepare and develop PLGA‐based nanoparticles that meet their specific demands.

1 December 1999 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
HSHongKee Sah
HongKee Sah
The objective of this study was to investigate the behaviors of proteins at the water/methylene chloride interface to better understand denaturing effects of emulsification upon proteins. Ribonuclease A (RNase) and human serum albumin (HSA) were used as model proteins throughout this study. Their behaviors at the interface were studied in terms of protein recovery after emulsification, interfacial protein aggregation, and dynamic interfacial tension. This study demonstrated that protein instability during emulsification was traced to consequences of the adsorption and conformational rearrangements of proteins at the water/methylene chloride interface. Compared to HSA, RNase was much more vulnerable to the interface-induced aggregation reactions that led to formation of water-insoluble aggregates upon emulsification. Even though HSA was almost completely recovered from the emulsified aqueous phase, the protein underwent dimerization and oligomerization reactions to some extent. The results also demonstrated that the extent of interfacial RNase aggregation was affected by its aqueous concentration and the presence of HSA. Interestingly, RNase stability during emulsification was almost achieved by dissolving an adequate quantity of HSA in the RNase solution. HSA seemed to compete for the interface site and to effectively keep RNase out the interface, minimizing the likelihood of the interface-induced RNase aggregation. These results indicated that competitive adsorption modes of proteins could be used to stabilize a protein of interest against the denaturing effects of emulsification.